Price
$2.92
Decreased by -6.71%
Dollar Volume (20D)
363.29 K
ADR%
9.44
Earnings Report Date (estimate)
Mar 14, 24
Shares Float
10.64 M
Shares Outstanding
13.77 M
Shares Short
301.45 K
Market Cap.
40.2 M
Beta
-1.83
Price / Earnings
N/A
20D Range
2.76 3.77
50D Range
2.76 5.28
200D Range
1.17 8.82
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 13, 23 -0.24
Increased by +25%
-0.27
Increased by +11.11%
Aug 11, 23 -0.28
Decreased by -7.69%
-0.27
Decreased by -3.7%
May 12, 23 -0.25
Increased by +3.85%
-0.29
Increased by +13.79%
Mar 15, 23 -0.28
Decreased by -27.27%
-0.35
Increased by +20%
Nov 10, 22 -0.32
Decreased by -52.38%
-0.28
Decreased by -14.29%
Aug 12, 22 -0.26
Increased by +54.39%
-0.33
Increased by +21.21%
May 10, 22 -0.26
Increased by +45.83%
-0.33
Increased by +21.21%
Mar 16, 22 -0.22
Decreased by -106.38%
-0.4
Increased by +45%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0
Decreased by N/A%
-3.11 M
Increased by +12.05%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0
Decreased by N/A%
-3.45 M
Decreased by -31.47%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0
Decreased by N/A%
-2.9 M
Decreased by -8.72%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0
Decreased by N/A%
2.03 M
Increased by +177.32%
Increased by +N/A%
Decreased by N/A%
Sep 30, 22 0
Decreased by N/A%
-3.54 M
Increased by +23.71%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by N/A%
-2.62 M
Increased by +34.55%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by N/A%
-2.67 M
Decreased by -81.11%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0
Decreased by N/A%
-2.63 M
Decreased by -140.35%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.